Close Menu

This story has been updated to include additional commentary from test developers.

NEW YORK – The US Food and Drug Administration on Tuesday published the first results of a limit of detection comparison of Emergency Use Authorized molecular diagnostic tests for SARS-CoV-2.

Reported as nucleic acid amplification test-detectable units (NDU) per milliliter, the limits of detection for the first batch of 55 tests reported differed by 10,000-fold.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.